KPTI

XPOVIO (Selinexor)

Multiple myeloma (Penta-Refractory) | STORM

Quarterly Sales (Approved)

Exp Date

August 4, 2020

Amp Volatility Score

27%

Catalyst Info & Data Links

TITLE: Quarterly Sales for XPOVIO (Selinexor) (FDA-approved drug)


WHAT IS THE CATALYST EVENT?

  • Quarterly sales 

  • On its Q1 2020 investor call, KPTI reported slightly decreased revenue for XPOVIO. Management noted challenges with new patient starts in March given Covid pandemic, and suggested that April saw some renewed prescription growth. The March numbers were disappointing because KPTI began the month with positive Boston results in earlier multiple myeloma patients, which might have fueled further growth of XPOVIO even before FDA approval in less heavily pre-treated patients.


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS 


PRESS RELEASE 

PRESENTATIONS


PUBLICATIONS




MECHANISM OF ACTION/RATIONALE

  • Nuclear export inhibitor

  • Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways

1. Increases nuclear levels and activation of tumor suppressor proteins

2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels

3. Retains activated glucocorticoid receptor in the nucleus

Updated by HC

KPTI, XPOVIO, SELINEXOR, Multiple myeloma (Penta-Refractory), STORM

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

KPTI's Upcoming ASCO Presentat...

We invest in KPTI because they have an enterprise value below $2 billion, and an approved oral blood cancer drug, XPOVIO (Selinexor), with a new mechanism of action and blockbuster potential. XPOVIO i...

KPTI dilution event not a surp...

After reporting positive top-line Phase 3 results today, KTPI announced a follow-on offering. I provide more details about why this is not surprising as a comment to my Amp educational video to follow...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon